Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis (NCT07547735) | Clinical Trial Compass
RecruitingPhase 2
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
China100 participantsStarted 2025-03-20
Plain-language summary
In recent years, the incidence rate and disability rate of osteoarthritis have continued to grow, and it has become a common chronic disease of elderly patients, second only to the "three highs", and poses a continuous threat to China's medical and health system and public health system. Knee osteoarthritis is the main type of osteoarthritis, ranking 11th in global disability diseases and 38th in disability adjusted life year loss, causing significant economic burden to patients, families, and society. At present, most of the treatment methods for KOA have limited efficacy, only relieving pain symptoms and cannot prevent cartilage damage and other tissue damage in the joints. Due to the limitations of adverse events, there is still no optimal treatment plan for KOA. Most studies believe that autologous mesenchymal stem cell transplantation is a new treatment method with good efficacy and good repair effect for mild to moderate cartilage defects. Given that there is currently no optimal treatment plan for KOA, human umbilical cord mesenchymal stem cell injection has potential development value and is of great significance for the treatment of KOA patients.
Who can participate
Age range40 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Prior to conducting any assessment, written informed consent must be obtained;
✓. Able to communicate well with researchers during screening, understand and comply with experimental requirements;
✓. Age range from 40 to 70 years old (including threshold), regardless of gender;
✓. Male weight ≥ 50 kg, female weight ≥ 45 kg, body mass index (BMI) within the range of 18-28 kg/m2 (including critical values);
✓. According to the diagnostic criteria for knee osteoarthritis in the "Guidelines for the Diagnosis and Treatment of Osteoarthritis (2018 Edition)", subjects diagnosed with knee osteoarthritis (see Annex 1 for details); The course of knee osteoarthritis is more than 4 weeks;
Exclusion criteria
✕. Individuals with a history of knee joint infection, surgery, and radiation therapy within 6 months prior to administration;
✕. Combined instability of the knee joint (anterior and posterior cruciate ligaments, medial and lateral collateral ligaments), rupture, relaxation, or external deformity of the knee joint;
What they're measuring
1
Changes in WOMAC score from baseline
Timeframe: From Baseline (0 Week) to post-dose, 4 weeks, 12 weeks, 24 weeks, and 48 weeks after treatment
Trial details
NCT IDNCT07547735
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
. According to researchers, diseases that may interfere with knee joint function assessment, such as symptomatic lower back pain, lumbar disc herniation, and hip joint pain in the target knee joint;
✕. According to the judgment of researchers, local diseases that may confuse knee joint function assessment include but are not limited to septic arthritis, reactive arthritis, clinically recurrent pseudogout, chondrocalcinosis, or joint fractures;
✕. Within 3 months prior to administration, any medication injection treatment (including intra-articular injection of growth factors, hormones, or sodium hyaluronate) or lavage surgery has been received in the knee joint (target side) cavity;
✕. Merge intra-articular or periarticular tumors (such as knee synovial chondroma, pigmented nodular synovitis, etc.);
✕. Various serious systemic diseases such as neurological disorders, respiratory disorders, heart diseases (NYHA grade III and above), and liver dysfunction (ALT\>3)×ULN or AST\>3×ULN, renal dysfunction Cr\>2×ULN or BUN\>2×ULN, coagulation dysfunction (INR\>1.5), or severe hematological disorders (such as grade 3 or above anemia, hemoglobin (Hb)\<8 g/dL, grade 2 or above thrombocytopenia, PLT\<75×10 \^ 9/L);
✕. Diagnosed as systemic inflammatory arthritis or connective tissue disease, including but not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, Paget's disease, systemic lupus erythematosus, or other systemic diseases that may confuse KOA assessment (such as fibromyalgia);